Sonnet BioTherapeutics (NASDAQ:SONN – Get Free Report) and Avalon GloboCare (NASDAQ:ALBT – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, institutional ownership, valuation and risk.
Profitability
This table compares Sonnet BioTherapeutics and Avalon GloboCare’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Sonnet BioTherapeutics | N/A | -777.92% | -271.32% |
| Avalon GloboCare | -647.29% | N/A | -50.13% |
Volatility and Risk
Sonnet BioTherapeutics has a beta of 0.98, indicating that its share price is 2% less volatile than the S&P 500. Comparatively, Avalon GloboCare has a beta of -0.03, indicating that its share price is 103% less volatile than the S&P 500.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Sonnet BioTherapeutics | 0 | 0 | 1 | 0 | 3.00 |
| Avalon GloboCare | 0 | 0 | 0 | 0 | 0.00 |
Sonnet BioTherapeutics presently has a consensus target price of $20.00, indicating a potential upside of 362.43%. Given Sonnet BioTherapeutics’ stronger consensus rating and higher probable upside, equities research analysts clearly believe Sonnet BioTherapeutics is more favorable than Avalon GloboCare.
Institutional and Insider Ownership
9.5% of Sonnet BioTherapeutics shares are held by institutional investors. Comparatively, 1.4% of Avalon GloboCare shares are held by institutional investors. 2.0% of Sonnet BioTherapeutics shares are held by insiders. Comparatively, 37.3% of Avalon GloboCare shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Valuation & Earnings
This table compares Sonnet BioTherapeutics and Avalon GloboCare”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Sonnet BioTherapeutics | $20,000.00 | 685.51 | -$7.44 million | N/A | N/A |
| Avalon GloboCare | $1.33 million | 3.87 | -$7.90 million | ($19.96) | -0.14 |
Sonnet BioTherapeutics has higher earnings, but lower revenue than Avalon GloboCare.
Summary
Sonnet BioTherapeutics beats Avalon GloboCare on 8 of the 12 factors compared between the two stocks.
About Sonnet BioTherapeutics
Sonnet BioTherapeutics Holdings, Inc., a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead product candidate is SON-1010, a fully human single-chain version of interleukin 12 that is in Phase 1b/2a clinical trial for the treatment of solid tumor indications, including ovarian cancer, non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6, which is in Phase 1b/I2a clinical trail to treat chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy; and SON-1210, a bispecific compound for solid tumor indications, including colorectal cancer. It has a license agreement with New Life Therapeutics Pte, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin-6; and strategic development collaboration with Sarcoma Oncology Center to advance SON-1210. The company is headquartered in Princeton, New Jersey.
About Avalon GloboCare
Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and China. The company develops and delivers transformative cellular therapeutics, precision diagnostics, and clinical laboratory services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells. It is also developing mRNA-based Flash-CAR cell therapy platform. In addition, the company develops Avalon clinical-grade tissue-specific exosome (ACTEX); AVA-Trap, a therapeutic program provides an effective therapeutic option to combat COVID-19 and other life-threatening conditions involving cytokine storms; offers therapeutic and diagnostic targets utilizing QTY-code protein design technology with Massachusetts Institute of Technology (MIT), including using the QTY code protein design technology for development of a hemofiltration device to treat Cytokine Storm; and provides co-development of next generation, transposon-based, multi-target CAR-T, CAR-NK, and other immune effector cell therapeutic modalities with Arbele Limited. Avalon GloboCare Corp. has strategic partnership with HydroPeptide, LLC to engage in co-development and commercialization of a series of clinical-grade, exosome-based cosmeceutical, and orthopedic products; and corporate research agreement with the University of Pittsburgh of the Commonwealth System of Higher Education. The company was founded in 2016 and is headquartered in Freehold, New Jersey.
Receive News & Ratings for Sonnet BioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sonnet BioTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
